Farnesyltransferase inhibitors: Molecular evidence of therapeutic efficacy in acute lymphoblastic leukemia through cyclin D1 inhibition

Anticancer Research

Volumn 32, Issue 3, 2012, Pages 831-838

  Costa, Carlos Bruno ^a,b   Casalta Lopes, JOAt̃O ^a   Andrade, Carlos ^a   Moreira, Diana ^a   Oliveira, Ana C ^a   Gonçalves, Ana C ^a,c   Alves, Vera ^d   Silva, Teresa ^d   Dourado, Marilia ^a   Nascimento Costa, José M ^a,e   Sarmento Ribeiro, Ana B ^a,c  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d UNIVERSITY OF COIMBRA   (Portugal)

^e CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

Author keywords

hydroxyfarnesyl pyrophosphonic acid; Acute lymphoblastic leukemia; Apoptosis; Cyclin D1; Farnesyltransferase inhibitors; Lamin A

Indexed keywords

ALPHA HYDROXYFARNESYLPHOSPHONIC ACID; CYCLIN D1; LAMIN A; LAMIN C;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; ENZYME ACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CELL LINE, TUMOR; CYCLIN D1; ENZYME INHIBITORS; FARNESOL; FARNESYLTRANSTRANSFERASE; HUMANS; PHOSPHONIC ACIDS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84858765853     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Karp J, Lancet J, Kaufmann S, End D, Wright J, Bol K, Horak I, Tidwell M, Liesveld J, Kottke T, Ange D, Buddharaju L, Gojo I, Highsmith W, Belly R, Hohl R, Rybak M, Thibault A and Joseph Rosenblatt: Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase I clinical-laboratory correlative trial. Blood 97: 3361-3369, 2001.
2. Pui C and Evans W: Treatment of acute lymphoblastic leukemia. New Engl J Med 354: 166-181, 2006.
3. Holleman A, Cheok M, der Boer M, Yang W, Veerman A, Kazemir K, Pei D, Cheng C, Pui C, Relling M, Janka-Schaub G, Pieters R and Evans W: Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. New Engl J Med 6: 533-542, 2004.
4. Brunner T, Hahn S, Gupta A, Muschel R, McKenna W and Bernhard E: Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations. Cancer Res 63: 5656-5668, 2003. (Pubitemid 37187458)
5. End D: Farnesyl protein transferase inhibitors and other therapies targeting the RAS signal transduction pathway. Invest New Drugs 17: 241-258, 1999.
6. Gibbs JB, Oliff A: The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu Rev Pharmacol Toxicol 37: 143-166, 1997. (Pubitemid 27238873)
7. Casey P, Solski P, Der C, Buss J: P21 RAS is modified by a farnesyl isoprenoid. Proc Natl Acad SciUSA 86: 8323-8327, 1989. (Pubitemid 19286052)
8. Cantley L: The phosphoinositide 3-kinase pathway. Science 296: 1655-1657, 2002.
9. Schaeffer H, Weber M: Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cel Biol 19: 2435-2444, 1999. (Pubitemid 29144487)
10. Kelloff G, Lubet R, Fay J, Steele V, Boone C, Crowell J and Sigman C: Farnseyl protein transferase inhibitors as potential cancer chemopreventives. Cancer Epidem Biomar 6: 267-282, 1997. (Pubitemid 27172892)
11. Jabbour E, Kantarjian H and Cortes J: Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mchanisms of action. Leukemia Lymphoma 45: 2187-2195, 2004. (Pubitemid 39504312)
12. Cox A and Der C: Farnesyltransferase inhibitors and cancer treatment: targeting simply RAS? Biochim Biophys Acta 1333: F51-F71, 1997. (Pubitemid 27359966)
13. Kurzrock R, Albitar M, Cortes, Jorge E, Estey, Elihu H, Faderl SH, Garcia-Manero G, Thomas DA, Giles FJ, Ryback MJ, Thibault A, De Porre P and Kantarjian HM: Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol 22: 1287-1292, 2004.
14. Adjei A, Erlichman C, Davis J, Cutler D, Sloan J, Marks R, Hanson L, Svingen P, Atherton P, Bishop WR, Kirschmeier P and Kaufmann SH: A phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res 60: 1871-1877, 2000. (Pubitemid 30207646)
15. Appels N, Beijnen J and Schellens J: Development of farnesyl transferase inhibitors: a review. Oncologist 10: 565-578, 2005. (Pubitemid 41429120)
16. 2/M cell cycle progression and apoptosis in huma pancreatic ductal adenocarcinoma cells. Neoplasia 2: 261-272, 2000.
17. Cortes J, Albitar M, Thomas D, Giles F, Kurzrock R, Thibault A,Rackoff W, Koller C, O'Brien S, Garcia-Manero G, Talpaz M and Kantarjian H: Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 101: 1692-1697, 2003. (Pubitemid 36237561)
18. Prendergast GC: Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects. Curr Opin Cell Biol 12: 166-173, 2000.
19. Lancet J and Karp J: Farnesyl transferase inhibitors in myeloid malignancies. Blood Rev 17: 123-129, 2003. (Pubitemid 36876672)
20. Lancet J and Karp J: Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. Blood 102: 3880-3889, 2003. (Pubitemid 37486966)
21. Cox A and Der C: Farnesyltransferase inhibitors: promises and realities. Curr Opin in Pharmacol 2: 388-393, 2002. (Pubitemid 34830969)
22. Adjei AA, Davis JN, Erlichman C, Svingen PA and Kaufmann SH: Comparison of potential markers of farnesyltransferase inhibition. Clin Cancer Res 6: 2318-2325, 2000. (Pubitemid 30399198)
23. Kilic F, Dalton M, Burrell S, Mayer J, Patterson S and Sinensky M: In vitro assay and characterization of the farnesylationdependent prelamin a endoprotease. J Biol Chem 272: 5298-5304, 1997. (Pubitemid 27090093)
24. Beck L, Hosick T and Sinensky M: Isoprenylation is required for the processing of the lamin A precursor. J Cell Biol 110: 1489-1499, 1990.
25. Alsina M, Fonseca R, Wilson EF, Belle AN, Gerbino E, Price-Troska, Overton RM, Ahmann G, Bruzek LM, Adjei AA, Kaufmann SH, Wright JJ, Sullivan D, Djulbegovic B, Cantor AB, Greipp PR, Dalton WS and Sebti SM: Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood 103: 3271-3277, 2004. (Pubitemid 38525650)
26. Harouseau JL: Farnesyltransferase inhibitors in hematologic malignancies. Blood Rev 21: 173-182, 2007.
27. Alao J, Gamble S, Stavropoulou A, Pomeranz K, Lam E, Coombes R and Vigushin D: The cyclin D1 proto-oncogene is sequestered in the cytoplasm of mammalian cancer cell lines. Mol Cancer 5: 7, 2006.
28. Appels N, Beijnen J and Schellens J: Development of farnesyl transferase inhibitors: a review. Oncologist 10: 565-578, 2005. (Pubitemid 41429120)
29. Adjei L, Davis J, Bruzek L, Erlichman C and Kaufmann S: Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. Clin Cancer Res 7: 1438-1445, 2001. (Pubitemid 32708700)
30. Zhang F, Kirschmeier P, Carr D, James L, Bond R, Wang L, Patton R, Windsor WT, Syto R, Zhang R and Bishop WR: Characterization of HA-RAS, N-RAS, KI-RAS4A, and KI-RAS4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I. J Biol Chem 272: 10232-10239, 1997. (Pubitemid 27171703)
31. Sebti S and Hamilton A: Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene 19: 6584-6593, 2000. (Pubitemid 32197696)
32. Nakajima A, Tauchi T, Sumi M, Bishop W and Ohyashiki K: Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells. MolCancer Ther 2: 219-224, 2003.
33. Hoover RR, Mahon F, Melo JV and Daley GQ: Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood 100: 1068-1071, 2000.